dabrafenib/trametinib for thyroid carcinoma, anaplastic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Jan 2023: Trial started, NCT06079333
  2. 12 Oct 2023: Trial registered, NCT06079333

The trials

NCT06079333: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

State
Under way
Phase
Phase 2
People
20 planned
Started
1 Jan 2023
Primary completion
1 Jan 2027
Arms
neo-adjuvant and adjuvant braf/mek-inhibition
Results
None posted
  1. 1 Jan 2023: Trial started
  2. 12 Oct 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.